男受被做哭激烈娇喘gv视频,成人片免费网站,今天高清视频免费播放作文,欧美大片ppt免费

　　2型糖尿病患者患心血管疾病的風險是非糖尿病人群的兩到四倍。冠狀動脈鈣化（CAC）測試有助醫生預測哪些糖尿病患者心臟疾病的風險最大，根據維克森林大學浸信會醫療中心的一項研究。

　　目前醫學界的指南推薦將所有糖尿病患者視為心血管疾病高風險人群，但維克森林浸信會的這項研究發現，CAC可以識別致命性心血管疾病高風險以及低風險的糖尿病患者。

　　"我們的研究結果挑戰了公認的醫學看法，即所有糖尿病患者心血管風險相同。CAC是預測不同風險水平的關鍵，"Donald Bowden博士，維克森林大學浸信會生物化學教授和資深作者。研究結果在線發表于十二月號刊《糖尿病護理》（Diabetes Care）雜志。

　　研究總共納入1123名34-86歲2型糖尿病患者，平均隨訪7.4年。這項研究的受試者來自北卡羅來納州西部的診所。

　　"高風險人群死于心血管疾病的風險是低風險人群的11倍。更精確的診斷風險水平可幫助醫生提供更有效的治療，并有望改善的結果，"研究人員說。

　　Coronary Calcium Score Predicts Cardiovascular Mortality in Diabetes

　　Subhashish Agarwal, Amanda J. Cox, David M. Herringto,et al

　　Abstract

　　OBJECTIVE

　　In type 2 diabetes mellitus (T2DM), it remains unclear whether coronary artery calcium (CAC) provides additional information about cardiovascular disease (CVD) mortality beyond the Framingham Risk Score (FRS) factors.

　　RESEARCH DESIGN AND METHODS

　　A total of 1,123 T2DM participants, ages 34–86 years, in the Diabetes Heart Study followed up for an average of 7.4 years were separated using baseline computed tomography scans of CAC (0–9, 10–99, 100–299, 300–999, and ≥1,000).

　　Logistic regression was performed to examine the association between CAC and CVD mortality adjusting for FRS.

　　Areas under the curve (AUC) with and without CAC were compared. Net reclassification improvement (NRI) compared FRS (model 1) versus FRS+CAC (model 2) using 7.4-year CVD mortality risk categories 0% to <7%, 7% to <20%, and ≥20%.

　　RESULTS

　　Overall, 8% of participants died of cardiovascular causes during follow-up. In multivariate analysis, the odds ratios (95% CI) for CVD mortality using CAC 0–9 as the reference group were, CAC 10–99: 2.93 (0.74–19.55); CAC 100–299: 3.17 (0.70–22.22); CAC 300–999: 4.41(1.15–29.00); and CAC ≥1,000: 11.23 (3.24–71.00). AUC (95% CI) without CAC was 0.70 (0.67–0.73), AUC with CAC was 0.75 (0.72–0.78), and NRI was 0.13 (0.07–0.19).

　　CONCLUSIONS

　　In T2DM, CAC predicts CVD mortality and meaningfully reclassifies participants, suggesting clinical utility as a risk stratification tool in a population already at increased CVD risk.